Patch-Test Patterns in 471 Woodworkers With Occupational Dermatitis
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, home or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at wood dust, resins and airborne occupational exposure. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 471 woodworkers with occupational dermatitis, 558 woodworkers without it and 39,759 other occupational-dermatitis patients |
| Design | Retrospective comparative patch-test network study, 1999–2023 |
| Timepoint | Twenty-four years of network consultations |
| Key result | Among affected woodworkers, 32.5% had allergic contact dermatitis, 63.5% hand involvement and 8.5% facial involvement; epoxy sensitization was 5.5%, Myroxylon 7.4%, propolis 5.6% and colophonium 5.3%. |
How to interpret the result
The study maps referral-clinic patterns and highlights resins and plant-derived allergens. The percentages should not be presented as prevalence in all woodworkers.
Important limitation: All groups were patch-tested clinic patients, test coverage varied by allergen, and sensitization does not establish that a workplace exposure caused the dermatitis.
Questionnaires, examinations, sensors, patch tests and administrative records answer different questions. A screening or monitoring result can guide the next step, but it does not diagnose the cause of one person’s rash. An association can identify a pattern worth investigating without proving that a single task, material or personal factor caused every event.
Questions a worker, family or clinician can ask next
- What exactly was measured: reported symptoms, visible signs, allergy, work loss or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the study compare groups or follow change over time, and what factors could still explain the difference?
- Would clinician examination, occupational-health review or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 41224355
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.